Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cholic acid in Smith-Lemli-Opitz syndrome
NCT03720990Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Mar 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cholic acid in Smith-Lemli-Opitz syndrome (SLOS), sponsored by University of Nebraska. Primary endpoint: Change in Plasma Cholesterol at 8 weeks. Started Mar 2021; status: completed.
02
Drugs
cholic acid
03
Conditions
Smith-Lemli-Opitz syndrome (SLOS)
Beyond the preview
Go deeper on NCT03720990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03720990.